The Metabolic Role of Mitochondria in the Perinatal Cardiac Development and Cardiovascular Diseases

Abstract

The heart, as the central organ of the circulatory system, undergoes distinct metabolic transitions from embryonic development through postnatal maturation. A key aspect of this transition is mitochondrial maturation, which is influenced by changes in oxygen levels and metabolic substrates. These changes regulate cardiac structure and function by affecting signaling pathways and transcription factors. In cardiovascular diseases, mitochondria play a crucial role in altering metabolic patterns, contributing to pathological remodeling and worsening disease outcomes. This article explores mitochondrial roles in both cardiac development and disease progression, offering insights into potential therapeutic interventions.

Keywords

diabetic cardiomyopathy / heart development / heart failure / metabolism / mitochondria

References

[1] S. S. Martin, A. W. Aday, N. B. Allen, et al., “2025 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association,” Circulation 151 (2025): e41–e660.

[2] K. Zou, G. Ding, and H. Huang, “Advances in Research Into Gamete and Embryo-Fetal Origins of Adult Diseases,” Science China Life Sciences 62 (2019): 360–368, https://doi.org/10.1007/s11427-018-9427-4.

[3] J. Gambardella, A. Lombardi, and G. Santulli, “Metabolic Flexibility of Mitochondria Plays a Key Role in Balancing Glucose and Fatty Acid Metabolism in the Diabetic Heart,” Diabetes 69 (2020): 2054–2057, https://doi.org/10.2337/dbi20-0024.

[4] S. Goffart, J. C. von Kleist-Retzow, and R. J. Wiesner, “Regulation of Mitochondrial Proliferation in the Heart: Power-Plant Failure Contributes to Cardiac Failure in Hypertrophy,” Cardiovascular Research 64 (2004): 198–207, https://doi.org/10.1016/j.cardiores.2004.06.030.

[5] F. Gao, T. Liang, Y. W. Lu, et al., “A Defect in Mitochondrial Protein Translation Influences Mitonuclear Communication in the Heart,” Nature Communications 14 (2023): 1595, https://doi.org/10.1038/s41467-023-37291-5.

[6] P. E. Morales, C. Arias-Durán, Y. Ávalos-Guajardo, et al., “Emerging Role of Mitophagy in Cardiovascular Physiology and Pathology,” Molecular Aspects of Medicine 71 (2020): 100822, https://doi.org/10.1016/j.mam.2019.09.006.

[7] G. Ikeda, M. R. Santoso, Y. Tada, et al., “Mitochondria-Rich Extracellular Vesicles from Autologous Stem Cell–Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium,” Journal of the American College of Cardiology 77 (2021): 1073–1088, https://doi.org/10.1016/j.jacc.2020.12.060.

[8] X. Li, F. Wu, S. Günther, et al., “Inhibition of Fatty Acid Oxidation Enables Heart Regeneration in Adult Mice,” Nature 622 (2023): 619–626, https://doi.org/10.1038/s41586-023-06585-5.

[9] K. I. Sereti, N. B. Nguyen, P. Kamran, et al., “Analysis of Cardiomyocyte Clonal Expansion During Mouse Heart Development and Injury,” Nature Communications 9 (2018): 754, https://doi.org/10.1038/s41467-018-02891-z.

[10] J. A. R. Lang, J. T. Pearson, C. Binder-Heschl, et al., “Increase in Pulmonary Blood Flow at Birth: Role of Oxygen and Lung Aeration,” Journal of Physiology 594 (2016): 1389–1398, https://doi.org/10.1113/JP270926.

[11] U. Schubert, M. Müller, M. Norman, and H. Abdul-Khaliq, “Transition From Fetal to Neonatal Life: Changes in Cardiac Function Assessed by Speckle-Tracking Echocardiography,” Early Human Development 89 (2013): 803–808, https://doi.org/10.1016/j.earlhumdev.2013.06.009.

[12] M. Annandale, L. J. Daniels, X. Li, et al., “Fructose Metabolism and Cardiac Metabolic Stress,” Frontiers in Pharmacology 12 (2021): 695486, https://doi.org/10.3389/fphar.2021.695486.

[13] A. C. Cardoso, N. T. Lam, J. J. Savla, et al., “Mitochondrial Substrate Utilization Regulates Cardiomyocyte Cell-Cycle Progression,” Nature Metabolism 2 (2020): 167–178, https://doi.org/10.1038/s42255-020-0169-x.

[14] C. Perrino, A. L. Barabási, G. Condorelli, et al., “Epigenomic and Transcriptomic Approaches in the Post-Genomic Era: Path to Novel Targets for Diagnosis and Therapy of the Ischaemic Heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart,” Cardiovascular Research 113 (2017): 725–736, https://doi.org/10.1093/cvr/cvx070.

[15] L. Sun, H. Zhang, and P. Gao, “Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer,” Protein Cell 13 (2022): 877–919, https://doi.org/10.1007/s13238-021-00846-7.

[16] S. Trefely, K. Huber, J. Liu, et al., “Quantitative Subcellular Acyl-CoA Analysis Reveals Distinct Nuclear Metabolism and Isoleucine-Dependent Histone Propionylation,” Molecular Cell 82 (2022): 447–462.e6, https://doi.org/10.1016/j.molcel.2021.11.006.

[17] A. Hinton., S. M. Claypool, K. Neikirk, et al., “Mitochondrial Structure and Function in Human Heart Failure,” Circulation Research 135 (2024): 372–396, https://doi.org/10.1161/CIRCRESAHA.124.323800.

[18] S. M. Ng, S. Neubauer, and O. J. Rider, “Myocardial Metabolism in Heart Failure,” Current Heart Failure Reports 20 (2023): 63–75, https://doi.org/10.1007/s11897-023-00589-y.

[19] F. Capone, C. Sotomayor-Flores, D. Bode, et al., “Cardiac Metabolism in HFpEF: From Fuel to Signalling,” Cardiovascular Research 118 (2023): 3556–3575, https://doi.org/10.1093/cvr/cvac166.

[20] S. Chen, Y. Zou, C. Song, et al., “The Role of Glycolytic Metabolic Pathways in Cardiovascular Disease and Potential Therapeutic Approaches,” Basic Research in Cardiology 118 (2023): 48, https://doi.org/10.1007/s00395-023-01018-w.

[21] S. C. Kolwicz., S. Purohit, and R. Tian, “Cardiac Metabolism and Its Interactions with Contraction, Growth, and Survival of Cardiomyocytes,” Circulation Research 113 (2013): 603–616, https://doi.org/10.1161/CIRCRESAHA.113.302095.

[22] Y. Nakada, D. C. Canseco, S. Thet, et al., “Hypoxia Induces Heart Regeneration in Adult Mice,” Nature 541 (2017): 222–227, https://doi.org/10.1038/nature20173.

[23] J. Bae, R. J. Salamon, E. B. Brandt, et al., “Malonate Promotes Adult Cardiomyocyte Proliferation and Heart Regeneration,” Circulation 143 (2021): 1973–1986, https://doi.org/10.1161/CIRCULATIONAHA.120.049952.

[24] J. Ritterhoff, S. Young, O. Villet, et al., “Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis,” Circulation Research 126 (2020): 182–196, https://doi.org/10.1161/CIRCRESAHA.119.315483.

[25] M. Onishi, K. Yamano, M. Sato, N. Matsuda, and K. Okamoto, “Molecular Mechanisms and Physiological Functions of Mitophagy,” Embo Journal 40 (2021): e104705, https://doi.org/10.15252/embj.2020104705.

[26] K. Okazaki and E. Maltepe, “Oxygen, Epigenetics and Stem Cell Fate,” Regenerative Medicine 1 (2006): 71–83, https://doi.org/10.2217/17460751.1.1.71.

[27] J. Piquereau and R. Ventura-Clapier, “Maturation of Cardiac Energy Metabolism During Perinatal Development,” Frontiers in Physiology 9 (2018): 959, https://doi.org/10.3389/fphys.2018.00959.

[28] K. T. Kuppusamy, D. C. Jones, H. Sperber, et al., “Let-7 Family of microRNA is Required for Maturation and Adult-Like Metabolism in Stem Cell-Derived Cardiomyocytes,” Proceedings National Academy of Science USA 112 (2015): E2785, https://doi.org/10.1073/pnas.1424042112.

[29] M. J. C. van Herwijnen, T. A. P. Driedonks, B. L. Snoek, et al., “Abundantly Present miRNAs in Milk-Derived Extracellular Vesicles Are Conserved Between Mammals,” Frontiers in Nutrition 5 (2018): 81.

[30] C. Correia, A. Koshkin, P. Duarte, et al., “Distinct Carbon Sources Affect Structural and Functional Maturation of Cardiomyocytes Derived From Human Pluripotent Stem Cells,” Scientific Reports 7 (2017): 8590, https://doi.org/10.1038/s41598-017-08713-4.

[31] N. Schraps, M. Tirre, S. Pyschny, et al., “Cardiomyocyte Maturation Alters Molecular Stress Response Capacities and Determines Cell Survival Upon Mitochondrial Dysfunction,” Free Radical Biology and Medicine 213 (2024): 248–265, https://doi.org/10.1016/j.freeradbiomed.2024.01.034.

[32] A. E. Atici, T. R. Crother, and M. Noval Rivas, “Mitochondrial Quality Control in Health and Cardiovascular Diseases,” Frontiers in Cell and Developmental Biology 11 (2023): 1290046, https://doi.org/10.3389/fcell.2023.1290046.

[33] H. Bugger and K. Pfeil, “Mitochondrial ROS in Myocardial Ischemia Reperfusion and Remodeling,” Biochimica et Biophysica Acta – Molecular Basis of Disease 1866 (2020): 165768, https://doi.org/10.1016/j.bbadis.2020.165768.

[34] S. Cai, M. Zhao, B. Zhou, et al., “Mitochondrial Dysfunction in Macrophages Promotes Inflammation and Suppresses Repair After Myocardial Infarction,” Journal of Clinical Investigation 133 (2023): e159498, https://doi.org/10.1172/JCI159498.

[35] Y. Chen, G. Wu, M. Li, et al., “LDHA-Mediated Metabolic Reprogramming Promoted Cardiomyocyte Proliferation by Alleviating ROS and Inducing M2 Macrophage Polarization,” Redox Biology 56 (2022): 102446, https://doi.org/10.1016/j.redox.2022.102446.

[36] N. Guimarães-Camboa, J. Stowe, I. Aneas, et al., “HIF1α Represses Cell Stress Pathways to Allow Proliferation of Hypoxic Fetal Cardiomyocytes,” Developmental Cell 33 (2015): 507–521, https://doi.org/10.1016/j.devcel.2015.04.021.

[37] A. Hoque, P. Sivakumaran, S. T. Bond, et al., “Mitochondrial Fission Protein Drp1 Inhibition Promotes Cardiac Mesodermal Differentiation of Human Pluripotent Stem Cells,” Cell Death Discovery 4 (2018): 39, https://doi.org/10.1038/s41420-018-0042-9.

[38] J. G. Lees, A. M. Kong, Y. C. Chen, et al., “Mitochondrial Dysfunction and the Impaired Adipogenic Differentiation of Human Mesenchymal Stem Cells,” Stem Cells International 2019 (2019): 6380135.

[39] J. L. Pohjoismäki, T. Boettger, Z. Liu, S. Goffart, M. Szibor, and T. Braun, “Oxidative Stress During Mitochondrial Biogenesis Compromises mtDNA Integrity in Growing Hearts and Induces a Global DNA Repair Response,” Nucleic Acids Research 40 (2012): 6595–6607, https://doi.org/10.1093/nar/gks301.

[40] G. C. Rowe, A. Jiang, and Z. Arany, “PGC-1 Coactivators in Cardiac Development and Disease,” Circulation Research 107 (2010): 825–838, https://doi.org/10.1161/CIRCRESAHA.110.223818.

[41] N. Li, Q. X. Zhu, G. Z. Li, T. Wang, and H. Zhou, “Empagliflozin Ameliorates Diabetic Cardiomyopathy Probably via Activating AMPK/PGC-1α and Inhibiting the RhoA/ROCK Pathway,” World Journal of Diabetes 14 (2023): 1862–1876, https://doi.org/10.4239/wjd.v14.i12.1862.

[42] A. Chowdhury, A. Boshnakovska, A. Aich, et al., “Metabolic Switch From Fatty Acid Oxidation to Glycolysis in Knock-in Mouse Model of Barth Syndrome,” EMBO Molecular Medicine 15 (2023): e17399, https://doi.org/10.15252/emmm.202317399.

[43] L. Zheng, J. Du, Z. Wang, Q. Zhou, X. Zhu, and J. W. Xiong, “Molecular Regulation of Myocardial Proliferation and Regeneration,” Cell Regen 10 (2021): 13, https://doi.org/10.1186/s13619-021-00075-7.

[44] M. T. Zhao, S. Ye, J. Su, and V. Garg, “Cardiomyocyte Proliferation and Maturation: Two Sides of the Same Coin for Heart Regeneration,” Frontiers in Cell and Developmental Biology 8 (2020): 594226, https://doi.org/10.3389/fcell.2020.594226.

[45] J. N. R. Peoples, T. Maxmillian, Q. Le, et al., “Metabolomics Reveals Critical Adrenergic Regulatory Checkpoints in Glycolysis and Pentose–Phosphate Pathways in Embryonic Heart,” Journal of Biological Chemistry 293 (2018): 6925–6941, https://doi.org/10.1074/jbc.RA118.002566.

[46] F. Merkuri, M. Rothstein, and M. Simoes-Costa, “Histone Lactylation Couples Cellular Metabolism With Developmental Gene Regulatory Networks,” Nature Communications 15 (2024): 90, https://doi.org/10.1038/s41467-023-44121-1.

[47] D. Hu, A. Linders, A. Yamak, et al., “Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1α and LDHA,” Circulation Research 123 (2018): 1066–1079, https://doi.org/10.1161/CIRCRESAHA.118.313249.

[48] S. Hashmi and H. R. Ahmad, “Molecular Switch Model for Cardiomyocyte Proliferation,” Cell Regeneration 8 (2019): 12–20, https://doi.org/10.1016/j.cr.2018.11.002.

[49] G. W. Dorn 2nd, R. B. Vega, and D. P. Kelly, “Mitochondrial Biogenesis and Dynamics in the Developing and Diseased Heart,” Genes & Development 29 (2015): 1981–1991, https://doi.org/10.1101/gad.269894.115.

[50] L. Ma, M. Shao, W. Cheng, et al., “Neocryptotanshinone Ameliorates Insufficient Energy Production in Heart Failure by Targeting Retinoid X Receptor Alpha,” Biomedicine & Pharmacotherapy 163 (2023): 114868, https://doi.org/10.1016/j.biopha.2023.114868.

[51] J. W. Snowdin, C. H. Hsiung, D. G. Kesterson, V. G. Kamath, and E. E. McKee, “Effects of Zidovudine Treatment on Heart mRNA Expression and Mitochondrial DNA Copy Number Associated With Alterations in Deoxynucleoside Triphosphate Composition in a Neonatal Rat Model,” Antimicrobial Agents and Chemotherapy 59 (2015): 6328–6336, https://doi.org/10.1128/AAC.01180-15.

[52] J. Kudová, J. Procházková, O. Vašiček, et al., “HIF-1alpha Deficiency Attenuates the Cardiomyogenesis of Mouse Embryonic Stem Cells,” PLoS ONE 11 (2016): e0158358, https://doi.org/10.1371/journal.pone.0158358.

[53] C. Gentillon, D. Li, M. Duan, et al., “Targeting HIF-1α in Combination With PPARα Activation and Postnatal Factors Promotes the Metabolic Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes,” Journal of Molecular and Cellular Cardiology 132 (2019): 120–135, https://doi.org/10.1016/j.yjmcc.2019.05.003.

[54] A. K. Knutson, A. L. Williams, W. A. Boisvert, and R. V. Shohet, “HIF in the Heart: Development, Metabolism, Ischemia, and Atherosclerosis,” Journal of Clinical Investigation 131 (2021): e137557, https://doi.org/10.1172/JCI137557.

[55] J. M. Quiles and Å. B. Gustafsson, “The Role of Mitochondrial Fission in Cardiovascular Health and Disease,” Nature Reviews Cardiology 19 (2022): 723–736, https://doi.org/10.1038/s41569-022-00703-y.

[56] X. Wang, G. Zhang, S. Dasgupta, et al., “ATF4 Protects the Heart from Failure by Antagonizing Oxidative Stress,” Circulation Research 131 (2022): 91–105, https://doi.org/10.1161/CIRCRESAHA.122.321050.

[57] G. Zanini, V. Selleri, M. Malerba, et al., “Mitochondrial Dysfunction and Oxidative Stress in Cardiovascular Diseases,” Antioxidants (Basel) 12 (2023): 1031.

[58] K. Zhao, X. Huang, W. Zhao, B. Lu, and Z. Yang, “Mitochondrial Dynamics Regulate Cardiomyocyte Proliferation During Heart Development,” Development (Cambridge, England) 149 (2022): dev200607.

[59] D. A. Bota and K. J. Davies, “Mitochondrial Lon Protease in Human Disease and Aging: Including an Etiologic Classification of Lon-Related Diseases and Disorders,” Free Radical Biology and Medicine 100 (2016): 188–198, https://doi.org/10.1016/j.freeradbiomed.2016.06.031.

[60] H. Nakano and A. Nakano, “The Role of Metabolism in Cardiac Development,” Current Topics in Developmental Biology 156 (2024): 201–243.

[61] A. S. Monzel, J. A. Enríquez, and M. Picard, “Multifaceted Mitochondria: Moving Mitochondrial Science Beyond Function and Dysfunction,” Nature Metabolism 5 (2023): 546–562, https://doi.org/10.1038/s42255-023-00783-1.

[62] C. Vásquez-Trincado, I. García-Carvajal, C. Pennanen, et al., “Mitochondrial Dynamics, Mitophagy and Cardiovascular Disease,” Journal of Physiology 594 (2016): 509–525, https://doi.org/10.1113/JP271301.

[63] M. Adebayo, S. Singh, A. P. Singh, and S. Dasgupta, “Mitochondrial Fusion and Fission: The Fine-Tune Balance for Cellular Homeostasis,” Faseb Journal 35 (2021): e21620, https://doi.org/10.1096/fj.202100067R.

[64] J. N. Meyer, T. C. Leuthner, and A. L. Luz, “Mitochondrial Fusion, Fission, and Mitochondrial Toxicity,” Toxicology 391 (2017): 42–53, https://doi.org/10.1016/j.tox.2017.07.019.

[65] T. Kleele, T. Rey, J. Winter, et al., “Distinct Fission Signatures Predict Mitochondrial Degradation or Biogenesis,” Nature 593 (2021): 435–439, https://doi.org/10.1038/s41586-021-03510-6.

[66] X. Liu, C. Guo, and Q. Zhang, “Novel Insights Into the Involvement of Mitochondrial Fission/Fusion in Heart Failure: From Molecular Mechanisms to Targeted Therapies,” Cell Stress & Chaperones 28 (2023): 133–144, https://doi.org/10.1007/s12192-023-01321-4.

[67] M. Tong, D. Zablocki, and J. Sadoshima, “The Role of Drp1 in Mitophagy and Cell Death in the Heart,” Journal of Molecular and Cellular Cardiology 142 (2020): 138–145, https://doi.org/10.1016/j.yjmcc.2020.04.015.

[68] Y. Hu, H. Chen, L. Zhang, et al., “The AMPK-MFN2 Axis Regulates MAM Dynamics and Autophagy Induced by Energy Stresses,” Autophagy 17 (2021): 1142–1156, https://doi.org/10.1080/15548627.2020.1749490.

[69] M. Ding, R. Shi, S. Cheng, et al., “Mfn2-Mediated Mitochondrial Fusion Alleviates Doxorubicin-Induced Cardiotoxicity With Enhancing Its Anticancer Activity Through Metabolic Switch,” Redox Biology 52 (2022): 102311, https://doi.org/10.1016/j.redox.2022.102311.

[70] G. Gong, M. Song, G. Csordas, D. P. Kelly, S. J. Matkovich, and G. W. Dorn 2nd, “Parkin-Mediated Mitophagy Directs Perinatal Cardiac Metabolic Maturation in Mice,” Science 350 (2015): aad2459, https://doi.org/10.1126/science.aad2459.

[71] Y. Chen and G. W. Dorn 2nd, “PINK1-Phosphorylated Mitofusin 2 Is a Parkin Receptor for Culling Damaged Mitochondria,” Science 340 (2013): 471–475, https://doi.org/10.1126/science.1231031.

[72] C. Cirotti, S. Rizza, P. Giglio, et al., “Redox Activation of ATM Enhances GSNOR Translation to Sustain Mitophagy and Tolerance to Oxidative Stress,” Embo Reports 22 (2021): e50500, https://doi.org/10.15252/embr.202050500.

[73] M. Lazarou, D. A. Sliter, L. A. Kane, et al., “The Ubiquitin Kinase PINK1 Recruits Autophagy Receptors to Induce Mitophagy,” Nature 524 (2015): 309–314, https://doi.org/10.1038/nature14893.

[74] T. Kataura, E. G. Otten, Y. Rabanal-Ruiz, et al., “NDP52 Acts as a Redox Sensor in PINK1/Parkin-Mediated Mitophagy,” Embo Journal 42 (2023): e111372, https://doi.org/10.15252/embj.2022111372.

[75] A. S. Moore and E. L. Holzbaur, “Dynamic Recruitment and Activation of ALS-Associated TBK1 With Its Target Optineurin Are Required for Efficient Mitophagy,” Proceedings National Academy of Science USA 113 (2016): E3349–E3358.

[76] B. Wang, J. Nie, L. Wu, et al., “AMPKα2 Protects Against the Development of Heart Failure by Enhancing Mitophagy via PINK1 Phosphorylation,” Circulation Research 122 (2018): 712–729, https://doi.org/10.1161/CIRCRESAHA.117.312317.

[77] C. Covill-Cooke, B. Kwizera, G. López-Doménech, et al., “Shared Structural Features of Miro Binding Control Mitochondrial Homeostasis,” Embo Journal 43 (2024): 595–614, https://doi.org/10.1038/s44318-024-00028-1.

[78] S. Geisler, K. M. Holmström, D. Skujat, et al., “PINK1/Parkin-Mediated Mitophagy Is Dependent on VDAC1 and p62/SQSTM1,” Nature Cell Biology 12 (2010): 119–131, https://doi.org/10.1038/ncb2012.

[79] J. Shi, G. Fung, H. Deng, et al., “NBR1 is Dispensable for PARK2-Mediated Mitophagy Regardless of the Presence or Absence of SQSTM1,” Cell Death & Disease 6 (2015): e1943, https://doi.org/10.1038/cddis.2015.278.

[80] J. M. Heo, A. Ordureau, J. A. Paulo, J. Rinehart, and J. W. Harper, “The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy,” Molecular Cell 60 (2015): 7–20, https://doi.org/10.1016/j.molcel.2015.08.016.

[81] M. Gersch, C. Gladkova, A. F. Schubert, M. A. Michel, S. Maslen, and D. Komander, “Mechanism and Regulation of the Lys6-Selective Deubiquitinase USP30,” Nature Structural & Molecular Biology 24 (2017): 920–930, https://doi.org/10.1038/nsmb.3475.

[82] P. Chang, H. Li, H. Hu, Y. Li, and T. Wang, “The Role of HDAC6 in Autophagy and NLRP3 Inflammasome,” Frontiers in Immunology 12 (2021): 763831, https://doi.org/10.3389/fimmu.2021.763831.

[83] J. Y. Jin, X. X. Wei, X. L. Zhi, X. H. Wang, and D. Meng, “DRP1-Dependent Mitochondrial Fission in Cardiovascular Disease,” Acta Pharmacologica Sinica 42 (2021): 655–664, https://doi.org/10.1038/s41401-020-00518-y.

[84] C. L. Hoppel, B. Tandler, H. Fujioka, and A. Riva, “Dynamic Organization of Mitochondria in Human Heart and in Myocardial Disease,” International Journal of Biochemistry & Cell Biology 41 (2009): 1949–1956, https://doi.org/10.1016/j.biocel.2009.05.004.

[85] D. A. Eisner, J. L. Caldwell, K. Kistamás, and A. W. Trafford, “Calcium and Excitation-Contraction Coupling in the Heart,” Circulation Research 121 (2017): 181–195, https://doi.org/10.1161/CIRCRESAHA.117.310230.

[86] M. Schwarzer, A. Schrepper, P. A. Amorim, M. Osterholt, and T. Doenst, “Pressure Overload Differentially Affects Respiratory Capacity in Interfibrillar and Subsarcolemmal Mitochondria,” American Journal of Physiology. Heart and Circulatory Physiology 304 (2013): H529–H537, https://doi.org/10.1152/ajpheart.00699.2012.

[87] C. M. Sag, S. Wagner, and L. S. Maier, “Role of Oxidants on Calcium and Sodium Movement in Healthy and Diseased Cardiac Myocytes,” Free Radical Biology and Medicine 63 (2013): 338–349, https://doi.org/10.1016/j.freeradbiomed.2013.05.035.

[88] X. Wei, A. C. H. Chang, H. Chang, et al., “Hypoglycemia-Exacerbated Mitochondrial Connexin 43 Accumulation Aggravates Cardiac Dysfunction in Diabetic Cardiomyopathy,” Frontiers in Cardiovascular Medicine 9 (2022): 800185, https://doi.org/10.3389/fcvm.2022.800185.

[89] S. Hamilton, R. Terentyeva, B. Martin, et al., “Increased RyR2 Activity is Exacerbated by Calcium Leak-Induced Mitochondrial ROS,” Basic Research in Cardiology 115 (2020): 38, https://doi.org/10.1007/s00395-020-0797-z.

[90] V. Lukyanenko, A. Chikando, and W. J. Lederer, “Mitochondria in Cardiomyocyte Ca²⁺ Signaling,” International Journal of Biochemistry & Cell Biology 41 (2009): 1957–1971, https://doi.org/10.1016/j.biocel.2009.03.011.

[91] L. Vetter, S. Cortassa, B. O'Rourke, et al., “Diabetes Increases the Vulnerability of the Cardiac Mitochondrial Network to Criticality,” Frontiers in Physiology 11 (2020): 175, https://doi.org/10.3389/fphys.2020.00175.

[92] L. W. Thomas and M. Ashcroft, “Exploring the Molecular Interface Between Hypoxia-Inducible Factor Signalling and Mitochondria,” Cellular and Molecular Life Sciences 76 (2019): 1759–1777, https://doi.org/10.1007/s00018-019-03039-y.

[93] Y. Shi, M. Tian, X. Zhao, et al., “α-Ketoglutarate Promotes Cardiomyocyte Proliferation and Heart Regeneration After Myocardial Infarction,” Nature Cardiovascular Research 3 (2024): 1083–1097, https://doi.org/10.1038/s44161-024-00531-y.

[94] J. M. do Carmo, A. C. M. Omoto, J. E. Hall, et al., “Parental Obesity Predisposes Male and Female Offspring to Exacerbated Cardiac Dysfunction and Increased Mortality After Myocardial Infarction,” American Journal of Physiology-Heart and Circulatory Physiology 328 (2025): H1039–H1050.

[95] A. L. K. Cochrane, M. P. Murphy, S. E. Ozanne, and D. A. Giussani, “Pregnancy in Obese Women and Mechanisms of Increased Cardiovascular Risk in Offspring,” European Heart Journal 45 (2024): 5127–5145, https://doi.org/10.1093/eurheartj/ehae671.

[96] N. Sinha, S. Roy, B. Huang, J. Wang, V. Padmanabhan, and A. Sen, “Developmental Programming: Prenatal Testosterone-Induced Epigenetic Modulation and Its Effect on Gene Expression in Sheep Ovary†,” Biology of Reproduction 102 (2020): 1045–1054, https://doi.org/10.1093/biolre/ioaa007.

[97] J. W. Palmer, B. Tandler, and C. L. Hoppel, “Biochemical Properties of Subsarcolemmal and Interfibrillar Mitochondria Isolated From Rat Cardiac Muscle,” Journal of Biological Chemistry 252 (1977): 8731–8739, https://doi.org/10.1016/S0021-9258(19)75283-1.

[98] M. Picard and O. S. Shirihai, “Mitochondrial Signal Transduction,” Cell Metabolism 34 (2022): 1620–1653, https://doi.org/10.1016/j.cmet.2022.10.008.

[99] L. Da Dalt, A. G. Cabodevilla, I. J. Goldberg, and G. D. Norata, “Cardiac Lipid Metabolism, Mitochondrial Function, and Heart Failure,” Cardiovascular Research 119 (2023): 1905.

[100] H. Wang, J. Wang, H. Cui, et al., “Inhibition of Fatty Acid Uptake by TGR5 Prevents Diabetic Cardiomyopathy,” Nature Metabolism 6 (2024): 1161–1177, https://doi.org/10.1038/s42255-024-01036-5.

[101] K. D. Wagner and N. Wagner, “PPARs and Angiogenesis—Implications in Pathology,” International Journal of Molecular Sciences 21 (2020): 5723.

[102] B. Zhou and R. Tian, “Mitochondrial Dysfunction in Pathophysiology of Heart Failure,” Journal of Clinical Investigation 128 (2018): 3716–3726, https://doi.org/10.1172/JCI120849.

[103] M. J. Hundertmark, A. Adler, C. Antoniades, et al., “Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients with Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial,” Circulation 147 (2023): 1654–1669, https://doi.org/10.1161/CIRCULATIONAHA.122.062021.

[104] G. Keceli, A. Gupta, J. Sourdon, et al., “Cardiomyocyte Mitochondrial Dysfunction in Heart Failure,” Circulation Research 130 (2022): 741.

[105] A. Gupta, A. Akki, Y. Wang, et al., “Creatine Kinase–Mediated Improvement of Function in Failing Mouse Hearts Provides Causal Evidence the Failing Heart Is Energy Starved,” Journal of Clinical Investigation 122 (2012): 291–302, https://doi.org/10.1172/JCI57426.

[106] T. H. Kimball and T. M. Vondriska, “Metabolism, Epigenetics, and Causal Inference in Heart Failure,” Trends in Endocrinology and Metabolism 31 (2020): 181–191, https://doi.org/10.1016/j.tem.2019.11.009.

[107] S. Givvimani, S. Pushpakumar, S. Veeranki, and S. C. Tyagi, “Dysregulation of Mfn2 and Drp-1 Proteins in Heart Failure,” Canadian Journal of Physiology and Pharmacology 92 (2014): 583–591, https://doi.org/10.1139/cjpp-2014-0060.

[108] N. Mendez-Barbero, J. Oller, A. B. Sanz, et al., “Oligo-Carrageenan Kappa Increases Expression of Genes Encoding Proteins Involved in Photosynthesis, C, N, and S Assimilation, and Growth in Arabidopsis thaliana,” International Journal of Molecular Sciences 24 (2023): 11894, https://doi.org/10.3390/ijms241511894.

[109] D. Tasić and Z. Dimitrijević, “Mitochondrial Dysfunction as a Biomarker in Cardiovascular Diseases,” Diagnostics (Basel) 14 (2024): 256.

[110] G. Guzmán Mentesana, A. L. Báez, M. S. Lo Presti, et al., “Functional and Structural Alterations of Cardiac and Skeletal Muscle Mitochondria in Heart Failure Patients,” Archives of Medical Research 45 (2014): 237–246, https://doi.org/10.1016/j.arcmed.2014.03.003.

[111] S. I. Oka, A. D. Sabry, K. M. Cawley, and J. S. Warren, “Multiple Levels of PGC-1α Dysregulation in Heart Failure,” Frontiers in Cardiovascular Medicine 7 (2020): 2, https://doi.org/10.3389/fcvm.2020.00002.

[112] Z. P. Ke, W. Q. Tao, G. Zhao, and K. Cheng, “Role of PPAR-Related Genes in Chronic Heart Failure: Evidence From Large Populations,” BMC Cardiovascular Disorders 23 (2023): 552, https://doi.org/10.1186/s12872-023-03554-8.

[113] S. Kasai, S. Shimizu, Y. Tatara, J. Mimura, and K. Itoh, “Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology,” Biomolecules 10 (2020): 320, https://doi.org/10.3390/biom10020320.

[114] V. Actis Dato, S. Lange, and Y. Cho, “Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases,” International Journal of Molecular Sciences 25 (2024): 1211.

[115] T. Sato and N. Takeda, “The Roles of HIF-1α Signaling in Cardiovascular Diseases,” Journal of Cardiology 81 (2023): 202–208, https://doi.org/10.1016/j.jjcc.2022.09.002.

[116] T. Kashihara, R. Mukai, S. I. Oka, et al., “YAP Mediates Compensatory Cardiac Hypertrophy Through Aerobic Glycolysis in Response to Pressure Overload,” Journal of Clinical Investigation 132 (2022): e150595, https://doi.org/10.1172/JCI150595.

[117] H. Tsutsui, S. Kinugawa, and S. Matsushima, “Oxidative Stress and Heart Failure,” American Journal of Physiology. Heart and Circulatory Physiology 301 (2011): H2181–H2190, https://doi.org/10.1152/ajpheart.00554.2011.

[118] M. A. D. Viloria, Q. Li, W. Lu, et al., “Effect of Exercise Training on Cardiac Mitochondrial Respiration, Biogenesis, Dynamics, and Mitophagy in Ischemic Heart Disease,” Frontiers in Cardiovascular Medicine 9 (2022): 949744, https://doi.org/10.3389/fcvm.2022.949744.

[119] B. De Geest and M. Mishra, “Role of Oxidative Stress in Heart Failure: Insights From Gene Transfer Studies,” Biomedicines 9 (2021): 1645.

[120] A. Gupta, S. Gupta, D. Young, B. Das, J. McMahon, and S. Sen, “Impairment of Ultrastructure and Cytoskeleton During Progression of Cardiac Hypertrophy to Heart Failure,” Laboratory Investigation 90 (2010): 520–530, https://doi.org/10.1038/labinvest.2010.43.

[121] L. X. Liu, X. H. Zheng, J. H. Hai, et al., “SIRT3 Regulates Cardiolipin Biosynthesis in Pressure Overload-Induced Cardiac Remodeling by PPARγ-Mediated Mechanism,” PLoS ONE 19 (2024): e0301990, https://doi.org/10.1371/journal.pone.0301990.

[122] J. Dudek, M. Hartmann, and P. Rehling, “The Role of Mitochondrial Cardiolipin in Heart Function and Its Implication in Cardiac Disease,” Biochimica et Biophysica Acta Molecular Basis of Disease 1865 (2019): 810–821, https://doi.org/10.1016/j.bbadis.2018.08.025.

[123] B. A. Stanley, V. Sivakumaran, S. Shi, et al., “Thioredoxin Reductase-2 Is Essential for Keeping Low Levels of H₂O₂ Emission From Isolated Heart Mitochondria,” Journal of Biological Chemistry 286 (2011): 33669–33677, https://doi.org/10.1074/jbc.M111.284612.

[124] Y. Liu, Y. Wang, Y. Bi, et al., “Emerging Role of Mitophagy in Heart Failure: From Molecular Mechanism to Targeted Therapy,” Cell Cycle 22 (2023): 906–918, https://doi.org/10.1080/15384101.2023.2167949.

[125] Y. M. Yoon, H. J. Kim, J. H. Lee, and S. H. Lee, “Mitochondrial Dynamics and Mitophagy in Cardiovascular Diseases,” International Journal of Molecular Sciences 20 (2019): 2433.

[126] J. Lin, J. Duan, Q. Wang, S. Xu, S. Zhou, and K. Yao, “Mitochondrial Dynamics and Mitophagy in Cardiometabolic Disease,” Frontiers in Cardiovascular Medicine 9 (2022): 917135, https://doi.org/10.3389/fcvm.2022.917135.

[127] S. A. Hasson, L. A. Kane, K. Yamano, et al., “High-Content Genome-Wide RNAi Screens Identify Regulators of Parkin Upstream of Mitophagy,” Nature 504 (2013): 291–295, https://doi.org/10.1038/nature12748.

[128] Q. G. Karwi, G. M. Uddin, K. L. Ho, and G. D. Lopaschuk, “Loss of Metabolic Flexibility in the Failing Heart,” Frontiers in Cardiovascular Medicine 5 (2018): 68, https://doi.org/10.3389/fcvm.2018.00068.

[129] W. D. Watson, P. G. Green, A. J. M. Lewis, et al., “Retained Metabolic Flexibility of the Failing Human Heart,” Circulation 148 (2023): 109–123, https://doi.org/10.1161/CIRCULATIONAHA.122.062166.

[130] L. de las Fuentes, P. Herrero, L. R. Peterson, D. P. Kelly, R. J. Gropler, and V. G. Dávila-Román, “Myocardial Fatty Acid Metabolism,” Hypertension 41 (2003): 83–87, https://doi.org/10.1161/01.HYP.0000047668.48494.39.

[131] W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk, “Myocardial Substrate Metabolism in the Normal and Failing Heart,” Physiological Reviews 85 (2005): 1093–1129, https://doi.org/10.1152/physrev.00006.2004.

[132] P. G. Sant'Ana, L. C. Tomasi, G. M. Murata, et al., “Hypoxia-Inducible Factor 1-Alpha and Glucose Metabolism During Cardiac Remodeling Progression From Hypertrophy to Heart Failure,” International Journal of Molecular Sciences 24 (2023): 6201.

[133] N. Fillmore, J. L. Levasseur, A. Fukushima, et al., “Uncoupling of Glycolysis From Glucose Oxidation Accompanies the Development of Heart Failure With Preserved Ejection Fraction,” Molecular Medicine 24 (2018): 3, https://doi.org/10.1186/s10020-018-0005-x.

[134] P. Lopez-Vazquez, M. Fernandez-Caggiano, E. Barge-Caballero, et al., “Reduced Mitochondrial Pyruvate Carrier Expression in Hearts With Heart Failure and Reduced Ejection Fraction Patients: Ischemic vs. Non-Ischemic Origin,” Frontiers in Cardiovascular Medicine 11 (2024): 1349417, https://doi.org/10.3389/fcvm.2024.1349417.

[135] L. Piao, Y. H. Fang, V. J. Cadete, et al., “The Inhibition of Pyruvate Dehydrogenase Kinase Improves Impaired Cardiac Function and Electrical Remodeling in Two Models of Right Ventricular Hypertrophy: Resuscitating the Hibernating Right Ventricle,” Journal of Molecular Medicine 88 (2010): 47–60, https://doi.org/10.1007/s00109-009-0524-6.

[136] A. A. Gibb and B. G. Hill, “Metabolic Coordination of Physiological and Pathological Cardiac Remodeling,” Circulation Research 123 (2018): 107–128, https://doi.org/10.1161/CIRCRESAHA.118.312017.

[137] R. Lahey, A. N. Carley, X. Wang, et al., “Enhanced Redox State and Efficiency of Glucose Oxidation With miR Based Suppression of Maladaptive NADPH-Dependent Malic Enzyme 1 Expression in Hypertrophied Hearts,” Circulation Research 122 (2018): 836–845, https://doi.org/10.1161/CIRCRESAHA.118.312660.

[138] S. Yoshikawa, M. Nagao, R. Toh, et al., “Inhibition of Glutaminase 1-Mediated Glutaminolysis Improves Pathological Cardiac Remodeling,” American Journal of Physiology. Heart and Circulatory Physiology 322 (2022): H749–H761, https://doi.org/10.1152/ajpheart.00692.2021.

[139] D. Shao, O. Villet, Z. Zhang, et al., “Glucose Promotes Cell Growth by Suppressing Branched-Chain Amino Acid Degradation,” Nature Communications 9 (2018): 2935, https://doi.org/10.1038/s41467-018-05362-7.

[140] B. K. Kundu, M. Zhong, S. Sen, G. Davogustto, S. R. Keller, and H. Taegtmeyer, “Remodeling of Glucose Metabolism Precedes Pressure Overload-Induced Left Ventricular Hypertrophy: Review of a Hypothesis,” Cardiology 130 (2015): 211–220, https://doi.org/10.1159/000369782.

[141] D. H. Tran and Z. V. Wang, “Glucose Metabolism in Cardiac Hypertrophy and Heart Failure,” Journal of the American Heart Association 8 (2019): e012673, https://doi.org/10.1161/JAHA.119.012673.

[142] P. Umapathi, O. O. Mesubi, P. S. Banerjee, et al., “Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death,” Circulation 143 (2021): 1687–1703, https://doi.org/10.1161/CIRCULATIONAHA.120.051911.

[143] A. A. Cluntun, R. Badolia, S. Lettlova, et al., “The Pyruvate-Lactate Axis Modulates Cardiac Hypertrophy and Heart Failure,” Cell Metabolism 33 (2021): 629.e10–648.e10, https://doi.org/10.1016/j.cmet.2020.12.003.

[144] S. Sankaralingam and G. D. Lopaschuk, “Cardiac Energy Metabolic Alterations in Pressure Overload–Induced Left and Right Heart Failure (2013 Grover Conference Series),” Pulmonary Circulation 5 (2015): 15–28, https://doi.org/10.1086/679608.

[145] V. L. da Silva, G. A. F. Mota, S. L. B. de Souza, et al., “Aerobic Exercise Training Improves Calcium Handling and Cardiac Function in Rats With Heart Failure Resulting From Aortic Stenosis,” International Journal of Molecular Sciences 24 (2023): 12306.

[146] Y. Zhang, P. V. Taufalele, J. D. Cochran, et al., “Mitochondrial Pyruvate Carriers Are Required for Myocardial Stress Adaptation,” Nature Metabolism 2 (2020): 1248–1264, https://doi.org/10.1038/s42255-020-00288-1.

[147] N. Dörmann, E. Hammer, K. Struckmann, et al., “Mitochondrial Dysfunction and Metabolic Remodeling in Heart Failure,” Frontiers in Cardiovascular Medicine 10 (2023): 1323760.

[148] T. Yamamoto and M. Sano, “Deranged Myocardial Fatty Acid Metabolism in Heart Failure,” International Journal of Molecular Sciences 23 (2022): 996.

[149] Y. Yu, C. Jin, C. Zhao, et al., “Serum Free Fatty Acids Independently Predict Adverse Outcomes in Acute Heart Failure Patients,” Frontiers in Cardiovascular Medicine 8 (2021): 761537, https://doi.org/10.3389/fcvm.2021.761537.

[150] L. Djousse, M. L. Biggs, N. R. Matthan, et al., “Serum Individual Nonesterified Fatty Acids and Risk of Heart Failure in Older Adults,” Cardiology 146 (2021): 351–358, https://doi.org/10.1159/000513917.

[151] N. H. Son, S. Yu, J. Tuinei, et al., “PPARγ-Induced Cardiolipotoxicity in Mice Is Ameliorated by PPARα Deficiency Despite Increases in Fatty Acid Oxidation,” Journal of Clinical Investigation 120 (2010): 3443–3454, https://doi.org/10.1172/JCI40905.

[152] W. Wang, L. Zhang, P. K. Battiprolu, et al., “Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction,” JACC: Basic to Translational Science 4 (2019): 385–400, https://doi.org/10.1016/j.jacbts.2019.02.003.

[153] V. Sharma, “Parallel Effects of β-Adrenoceptor Blockade on Cardiac Function and Fatty Acid Oxidation in the Diabetic Heart: Confronting the Maze,” World Journal of Cardiology 3 (2011): 281, https://doi.org/10.4330/wjc.v3.i9.281.

[154] M. Bayeva, M. Gheorghiade, and H. Ardehali, “Mitochondria as a Therapeutic Target in Heart Failure,” Journal of the American College of Cardiology 61 (2013): 599–610, https://doi.org/10.1016/j.jacc.2012.08.1021.

[155] C. Caffarra Malvezzi, A. Cabassi, and M. Miragoli, “Mitochondrial Mechanosensor in Cardiovascular Diseases,” Vascular Biology 2 (2020): R85–R92, https://doi.org/10.1530/VB-20-0002.

[156] V. Weixler, R. Lapusca, G. Grangl, et al., “Autogenous Mitochondria Transplantation for Treatment of Right Heart Failure,” Journal of Thoracic and Cardiovascular Surgery 162 (2021): e111–e121, https://doi.org/10.1016/j.jtcvs.2020.08.011.

[157] G. Jia, A. Whaley-Connell, and J. R. Sowers, “Diabetic Cardiomyopathy: A Hyperglycaemia- and Insulin-Resistance-Induced Heart Disease,” Diabetologia 61 (2018): 21–28, https://doi.org/10.1007/s00125-017-4390-4.

[158] R. H. Ritchie and E. D. Abel, “Basic Mechanisms of Diabetic Heart Disease,” Circulation Research 126 (2020): 1501–1525, https://doi.org/10.1161/CIRCRESAHA.120.315913.

[159] W. H. Dillmann, “Diabetic Cardiomyopathy,” Circulation Research 124 (2019): 1160–1162, https://doi.org/10.1161/CIRCRESAHA.118.314665.

[160] V. S. Hahn, C. Petucci, M. S. Kim, et al., “Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction,” Circulation 147 (2023): 1147–1161, https://doi.org/10.1161/CIRCULATIONAHA.122.061846.

[161] F. Zhi, Q. Zhang, L. Liu, X. Chang, and H. Xu, “Novel Insights Into the Role of Mitochondria in Diabetic Cardiomyopathy: Molecular Mechanisms and Potential Treatments,” Cell Stress & Chaperones 28 (2023): 641–655, https://doi.org/10.1007/s12192-023-01361-w.

[162] Q. Hu, H. Zhang, N. Gutiérrez Cortés, et al., “Increased Drp1 Acetylation by Lipid Overload Induces Cardiomyocyte Death and Heart Dysfunction,” Circulation Research 126 (2020): 456–470, https://doi.org/10.1161/CIRCRESAHA.119.315252.

[163] J. Nan, W. Zhu, M. S. Rahman, et al., “Molecular Regulation of Mitochondrial Dynamics in Cardiac Disease,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864 (2017): 1260–1273, https://doi.org/10.1016/j.bbamcr.2017.03.006.

[164] E. Li, X. Li, J. Huang, et al., “BMAL1 regulates Mitochondrial Fission and Mitophagy Through Mitochondrial Protein BNIP3 and Is Critical in the Development of Dilated Cardiomyopathy,” Protein Cell 11 (2020): 661–679, https://doi.org/10.1007/s13238-020-00713-x.

[165] Y. Li, J. Cui, L. Liu, et al., “mtDNA Release Promotes cGAS-STING Activation and Accelerated Aging of Postmitotic Muscle Cells,” Cell Death & Disease 15 (2024): 523, https://doi.org/10.1038/s41419-024-06863-8.

[166] X. M. Ma, K. Geng, B. Y. Law, et al., “Lipotoxicity-Induced mtDNA Release Promotes Diabetic Cardiomyopathy by Activating the cGAS-STING Pathway in Obesity-Related Diabetes,” Cell Biology and Toxicology 39 (2023): 277–299, https://doi.org/10.1007/s10565-021-09692-z.

[167] M. Yan, Y. Li, Q. Luo, et al., “Mitochondrial Damage and Activation of the Cytosolic DNA Sensor cGAS–STING Pathway Lead to Cardiac Pyroptosis and Hypertrophy in Diabetic Cardiomyopathy Mice,” Cell Death Discovery 8 (2022): 258, https://doi.org/10.1038/s41420-022-01046-w.

[168] D. A. Sliter, J. Martinez, L. Hao, et al., “RETRACTED ARTICLE: Parkin and PINK1 Mitigate STING-Induced Inflammation,” Nature 561 (2018): 258–262, https://doi.org/10.1038/s41586-018-0448-9.

[169] F. Cividini, B. T. Scott, J. Suarez, et al., “Ncor2/PPARα-Dependent Upregulation of MCUb in the Type 2 Diabetic Heart Impacts Cardiac Metabolic Flexibility and Function,” Diabetes 70 (2021): 665–679, https://doi.org/10.2337/db20-0779.

[170] J. Diaz-Juarez, J. Suarez, F. Cividini, et al., “Expression of the Mitochondrial Calcium Uniporter in Cardiac Myocytes Improves Impaired Mitochondrial Calcium Handling and Metabolism in Simulated Hyperglycemia,” American Journal of Physiology—Cell Physiology 311 (2016): C1005–C1013, https://doi.org/10.1152/ajpcell.00236.2016.

[171] Z. Song, H. Song, D. Liu, et al., “Overexpression of MFN2 Alleviates Sorafenib-Induced Cardiomyocyte Necroptosis via the MAM-CaMKIIδ Pathway In Vitro and In Vivo,” Theranostics 12 (2022): 1267–1285, https://doi.org/10.7150/thno.65716.

[172] Y. Liu, J. L. Huo, K. Ren, et al., “Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM): A Dark Horse for Diabetic Cardiomyopathy Treatment,” Cell Death Discovery 10 (2024): 148, https://doi.org/10.1038/s41420-024-01918-3.

[173] J. Nan, J. Li, Y. Lin, M. Saif Ur Rahman, Z. Li, and L. Zhu, “The Interplay Between Mitochondria and Store-Operated Ca²⁺ Entry: Emerging Insights Into Cardiac Diseases,” Journal of Cellular and Molecular Medicine 25 (2021): 9496–9512, https://doi.org/10.1111/jcmm.16941.

[174] X. Feng, S. Wang, X. Yang, et al., “Mst1 Knockout Alleviates Mitochondrial Fission and Mitigates Left Ventricular Remodeling in the Development of Diabetic Cardiomyopathy,” Frontiers in Cell and Developmental Biology 8 (2020): 628842, https://doi.org/10.3389/fcell.2020.628842.

[175] J. Hu, T. Liu, F. Fu, et al., “Omentin1 Ameliorates Myocardial Ischemia-Induced Heart Failure via SIRT3/FOXO3a-Dependent Mitochondrial Dynamical Homeostasis and Mitophagy,” Journal of Translational Medicine 20 (2022): 447, https://doi.org/10.1186/s12967-022-03642-x.

[176] Y. M. Searls, I. V. Smirnova, B. R. Fegley, and L. Stehno-Bittel, “Exercise Attenuates Diabetes-Induced Ultrastructural Changes in Rat Cardiac Tissue,” Medicine and Science in Sports and Exercise 36 (2004): 1863–1870, https://doi.org/10.1249/01.MSS.0000145461.38224.EC.

[177] W. Yu, B. Gao, N. Li, et al., “Sirt3 Deficiency Exacerbates Diabetic Cardiac Dysfunction: Role of Foxo3A-Parkin-Mediated Mitophagy,” Biochimica et Biophysica Acta Molecular Basis of Disease 1863 (2017): 1973–1983, https://doi.org/10.1016/j.bbadis.2016.10.021.

[178] J. Nah, A. Shirakabe, R. Mukai, et al., “Ulk1-Dependent Alternative Mitophagy Plays a Protective Role During Pressure Overload in the Heart,” Cardiovascular Research 118 (2022): 2638–2651, https://doi.org/10.1093/cvr/cvac003.

[179] Z. Yin, Y. Zhao, M. He, et al., “MiR-30c/PGC-1β Protects Against Diabetic Cardiomyopathy via PPARα,” Cardiovascular Diabetology 18 (2019): 7, https://doi.org/10.1186/s12933-019-0811-7.

[180] L. Pulakat, V. G. DeMarco, A. Whaley-Connell, and J. R. Sowers, “The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney,” Cardiorenal Medicine 1 (2011): 102–112, https://doi.org/10.1159/000327140.

[181] J. Luiken, M. Nabben, D. Neumann, and J. F. C. Glatz, “Understanding the Distinct Subcellular Trafficking of CD36 and GLUT4 During the Development of Myocardial Insulin Resistance,” Biochimica et Biophysica Acta Molecular Basis of Disease 1866 (2020): 165775, https://doi.org/10.1016/j.bbadis.2020.165775.

[182] L. K. Steinbusch, R. W. Schwenk, D. M. Ouwens, M. Diamant, J. F. Glatz, and J. J. Luiken, “Subcellular Trafficking of the Substrate Transporters GLUT4 and CD36 in Cardiomyocytes,” Cellular and Molecular Life Sciences 68 (2011): 2525–2538, https://doi.org/10.1007/s00018-011-0690-x.

[183] D. Shao and R. Tian, “Glucose Transporters in Cardiac Metabolism and Hypertrophy,” Comprehensive Physiology 6 (2015): 331–351, https://doi.org/10.1002/j.2040-4603.2016.tb00680.x.

[184] A. Sahraoui, C. Dewachter, G. Vegh, et al., “High Fat Diet Altered Cardiac Metabolic Gene Profile in Psammomys obesus Gerbils,” Lipids in Health and Disease 19 (2020): 123, https://doi.org/10.1186/s12944-020-01301-y.

[185] K. Sikder, S. K. Shukla, N. Patel, H. Singh, and K. Rafiq, “High Fat Diet Upregulates Fatty Acid Oxidation and Ketogenesis via Intervention of PPAR-γ,” Cellular Physiology and Biochemistry 48 (2018): 1317–1331, https://doi.org/10.1159/000492091.

[186] Z. Guo, D. Huang, X. Tang, J. Han, and J. Li, “Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Role of Oxidative Stress and Calcium Handling,” Bosnian Journal of Basic Medical Sciences 15 (2015): 15.

[187] M. Tang, M. Zhong, Y. Shang, et al., “Differential Regulation of Collagen Types I and III Expression in Cardiac Fibroblasts by AGEs Through TRB3/MAPK Signaling Pathway,” Cellular and Molecular Life Sciences 65 (2008): 2924–2932, https://doi.org/10.1007/s00018-008-8255-3.

[188] F. Scavello, F. Zeni, G. Milano, et al., “Soluble Receptor for Advanced Glycation End-Products Regulates Age-Associated Cardiac Fibrosis,” International Journal of Biological Sciences 17 (2021): 2399–2416, https://doi.org/10.7150/ijbs.56379.

[189] S. Ducheix, J. Magré, B. Cariou, and X. Prieur, “Chronic O-GlcNAcylation and Diabetic Cardiomyopathy: The Bitterness of Glucose,” Front Endocrinol (Lausanne) 9 (2018): 642, https://doi.org/10.3389/fendo.2018.00642.

[190] H. Du, Y. Ma, X. Wang, et al., “Advanced Glycation End Products Induce Skeletal Muscle Atrophy and Insulin Resistance via Activating ROS-Mediated ER Stress PERK/FOXO1 Signaling,” American Journal of Physiology. Endocrinology and Metabolism 324 (2023): E279–E287, https://doi.org/10.1152/ajpendo.00218.2022.

[191] M. K. Brahma, M. E. Pepin, and A. R. Wende, “My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy,” Diabetes & Metabolism Journal 41 (2017): 1, https://doi.org/10.4093/dmj.2017.41.1.1.

[192] H. Shu, Y. Peng, W. Hang, J. Nie, N. Zhou, and D. W. Wang, “The Role of CD36 in Cardiovascular Disease,” Cardiovascular Research 118 (2022): 115–129, https://doi.org/10.1093/cvr/cvaa319.

[193] Q. G. Karwi, Q. Sun, and G. D. Lopaschuk, “The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity,” Cells 10 (2021): 3259, https://doi.org/10.3390/cells10113259.

[194] L. Dehina, J. Descotes, P. Chevalier, et al., “Protective Effects of Ranolazine and Propranolol, Alone or Combined, on the Structural and Functional Alterations of Cardiomyocyte Mitochondria in a Pig Model of Ischemia/Reperfusion,” Fundamental and Clinical Pharmacology 28 (2014): 257–267, https://doi.org/10.1111/fcp.12033.

[195] R. Wang, T. Miura, N. Harada, et al., “Pleiotropic Effects of the β-Adrenoceptor Blocker Carvedilol on Calcium Regulation During Oxidative Stress-Induced Apoptosis in Cardiomyocytes,” Journal of Pharmacology and Experimental Therapeutics 318 (2006): 45–52, https://doi.org/10.1124/jpet.105.099903.

RIGHTS & PERMISSIONS

2026 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.